The FDA has approved Zepbound, the first prescription medication for treating moderate to severe obstructive sleep apnea in individuals with obesity. Developed by Eli Lilly, Zepbound not only aids in weight loss but significantly reduces symptoms associated with sleep apnea, offering a new hope for millions affected by this sleep disorder. For more details about the story, visit our website.
#FDAApproval #Zepbound #WeightLoss #ObstructiveSleepApnea #EliLilly #GLP-1ReceptorAgonists #HealthNews #SleepDisorders #ObesityTreatment #Tirzepatide
Read full article: [ Ссылка ]
